References
- Aronoff G. R., Ozawa T., De Sante K. A., Nash J. F., Ridolfo A. S. Benoxaprofen kinetics in renal impairment. Clinical Pharmacology and Therapeutics 1982; 32: 190–194
- Bakke O. M., Draffan G. H., Davies D. S. The metabolism of phenylbutazone in the rat. Xenobiotica 1974; 4: 237–254
- Berry D. J. The disposition and pharmacokinetics of feprazone in human subjects. PhD Thesis, University of Surrey. 1982
- Berry D. J., Crome P., Corless D., Parke D. V. The pharmacokinetics of single oral doses of feprazone in healthy volunteers and elderly patients. Xenobiotica 1991; 21: 1211–1216
- Berry D. J., Parke D. V. The disposition of feprazone and its hydroxylated metabolite in human volunteers. Xenobiotica 1988a; 18: 857–868
- Berry D. J., Parke D. V. The micro gas-liquid chromatographic analysis of 4-(3′,3′-dimethylallyl)-1,2-(diphenylpyrazolidine)-3,5-dione (feprazone) in human biosamples. Journal of Pharmaceutical and Biomedical Analysis 1988b; 6: 493–501
- Billings R., Burry H. C., Grahame R., Berry D. J., Donovan B. A double-blind cross-over trial of prenazone and aspirin in the management of rheumatoid arthritis. Rheumatology and Rehabilitation 1975; 14: 61–70
- Cassadio S., Pala G., Marazzi-Uberti E., Lumachi B., Crescenzi E., Donetti A., Mantegani A., Bianchi C. Terpene compounds as drugs. X. 4-Prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370): a new anti-inflammatory drug, with low ulcerogenic effects, derived from a series of terpenyl pyrazolidinediones. Arzneimittel-Forschung 1972; 22: 171–174
- Donetti A., Quintero M. G., Cereda A., Yamaguchi H. Mass spectrometric identification of feprazone metabolites in rat, dog and man. Recent Developments in Mass Spectrometry in Biochemistry and MedicineVol. 6, A. Frigerio, M. McCamish. Elsevier, Amsterdam 1980; 203–215
- Eason C. T., Bonner F. W., Parke D. V. The importance of pharmacokinetics and receptor studies in drug safety evaluation. Regulatory Toxicology and Pharmacology 1990; 11: 288–307
- Fletcher M. R., Loebl W., Scott J. T. Feprazone, a new anti-inflammatory agent Studies of potency and gastrointestinal tolerance. Annals of Rheumatic Diseases 1975; 34: 190–194
- Gaetani M., Yamaguchi H., Vidi A., Hashimoto Y., Donetti A. Species differences in the metabolism of feprazone, an anti-inflammatory drug. Pharmacologic Research Communications 1979; 11: 719–730
- Lindup W. E., Henderson S. J., Barker C. E. Drug binding in renal disease. Plasma Binding of Drugs and its Consequences, F. Belpaire, M. Bogaert, J. P. Tillement, R. Verbeeck. Academic, Ghent 1991; 103–120
- Liu P. T., Symons A. M., Parke D. V. Autoxidative injury with loss of cytochrome P-450 following acute exposure of rats to fasting and ether anaesthesia. Xenobiotica 1991; 21: 205–215
- Parke D. V. Metabolism of drugs in the elderly. British Journal of Clinical Practice 1978; 32: 122–126, Suppl. 2
- Parke D. V. Adverse effects of drugs. Journal of the Royal Society of Health 1985; 105: 39–46
- Parke A. L., Ioannides C., Lewis D. F. V., Parke D. V. Molecular pathology of drug-disease interactions in chronic autoimmune inflammatory disease. Inflammopharmacology 1991; 1: 3–36
- Toft P., Dring L. G., Hirom P. C., Williams R. T., Donetti A., Midgley J. M. The metabolism of [14C]prenazone in the rat. Xenobiotica 1975; 5: 729–739
- Triggs E. J., Nation R. L., Long A., Ashley J. J. Pharmacokinetics and the elderly. European Journal of Clinical Pharmacology 1975; 8: 55–62
- Yamaguchi H., Kubo J., Sekine K., Naruchi T., Hashimoto Y., Kato R. Metabolites of feprazone in man. Drug Metabolism and Disposition 1979; 7: 340–344